We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis (gMG) whose symptoms are not controlled by existing treatments.
A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.
Page 1 of 47